神经性疼痛治疗​​市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球神经性疼痛治疗​​市场价值为 82 亿美元，预计到 2034 年将以 8.3% 的复合年增长率成长，达到 181 亿美元。这一强劲的成长轨迹是由全球神经性疼痛疾病负担不断增加所推动的，而推动这一负担增加的因素包括全球人口老化、生活方式相关疾病以及糖尿病和癌症等慢性病激增。随着人们对神经相关疼痛及其致残影响的认识不断提高，对早期诊断和有效治疗策略的需求持续飙升。不断变化的患者偏好进一步推动了市场的发展，由于政府监管的严格和日益增长的安全问题，患者对阿片类药物的治疗方式显着减少。药物传输系统、生物技术和新配方的进步为治疗领域打开了新的大门。数位健康平台和远距医疗服务的出现增强了人们获得专科护理的机会，特别是在服务不足的地区，加快了神经病的诊断和及时干预。

慢性疼痛的日益普及以及对更安全的治疗方案的迫切需求正在推动下一代疗法的发展。製造商正专注于创新药物管道，包括非鸦片类药物、基因疗法、单株抗体和生物相似药，旨在解决急性和慢性神经性疼痛。这些突破性疗法旨在提供有针对性的、持久的缓解，同时最大限度地减少副作用，代表疼痛管理领域的重大飞跃。

根据药物类别，抗惊厥药物继续占据市场主导地位，预计将以 8.5% 的复合年增长率增长，到 2034 年达到 78 亿美元。普瑞巴林、加巴喷丁和卡马西平等广泛使用的药物因其高效性和良好的安全性而被公认为一线治疗药物。它们的广泛用途尤其显着地体现在治疗糖尿病引起的神经病变、带状疱疹后神经痛和脊髓损伤方面。随着慢性病发病率的上升，这些经过验证的药物的采用率也在上升，巩固了它们在市场上的地位。

从适应症来看，糖尿病神经病变在 2024 年的收入为 30 亿美元。全球糖尿病患者数量的不断增加对长期治疗方案产生了持续的需求。保险覆盖范围的扩大和神经病治疗报销的增加使得患者更容易接受普瑞巴林和辣椒素贴片等疗法，从而提高了依从性和治疗效果。

光是美国神经性疼痛治疗​​市场在 2024 年的价值就达到 33 亿美元，预计未来将显着成长。这种增长主要是由于该国人口老化以及癌症、糖尿病和带状疱疹等疾病的发病率上升。联邦政府对阿片类药物处方的限制也增强了对非鸦片类药物替代品的需求，促使治疗模式发生重大转变。

Assertio Therapeutics、Glenmark Pharmaceuticals、Cipla、Dr. Reddy's Laboratories、强生、礼来公司、葛兰素史克、Biogen、Grunenthal、Mallinckrodt Pharmaceuticals、诺华、辉瑞、Sun Pharmaceutical Industries、Teva Pharmaceutical Industriest Pharmaceuticals、诺华、辉瑞、Sun Pharmaceutical Industries、Teva Pharmaceutical Industriest 和 Ver这些公司正在积极扩大其治疗管道，并与研究机构建立策略联盟，以更快、更有效地将新型治疗方法推向市场。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 神经性疼痛疾病盛行率上升
    • 药物开发和新疗法的进展
    • 老年人口不断增加
    • 提高及时治疗的意识
  • 产业陷阱与挑战
    • 神经性疼痛药物成本高昂
    • 药物滥用的副作用和风险
• 成长潜力分析
• 监管格局
• 技术格局
• 管道分析
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按药物类别，2021 - 2034 年

• 主要趋势
• 抗惊厥药
• 抗忧郁药
• 阿片类药物
• 辣椒素
• 其他药物类别

第六章：市场估计与预测：按适应症，2021 - 2034 年

• 主要趋势
• 糖尿病神经病变
• 带状疱疹后神经痛
• 三叉神经痛
• 化疗引起的周边神经病变
• HIV相关神经病变
• 其他适应症

第七章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 外用
• 注射剂

第八章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 电子商务

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Assertio Therapeutics
• Biogen
• Cipla
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Grunenthal
• Johnson & Johnson
• Mallinckrodt Pharmaceuticals
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Vertex Pharmaceuticals

The Global Neuropathic Pain Treatment Market was valued at USD 8.2 billion in 2024 and is estimated to grow at a CAGR of 8.3% to reach USD 18.1 billion by 2034. This robust growth trajectory is fueled by a rising burden of neuropathic pain disorders worldwide, fueled by factors such as an aging global population, lifestyle-related diseases, and a surge in chronic conditions like diabetes and cancer. As awareness about nerve-related pain and its debilitating effects increases, the demand for early diagnosis and effective treatment strategies continues to soar. The market is further propelled by evolving patient preferences, with a significant shift away from opioid-based therapies due to stringent government regulations and growing safety concerns. Advancements in drug delivery systems, biotechnology, and novel formulations have opened new doors for the treatment landscape. The availability of digital health platforms and telemedicine services is enhancing access to specialized care, particularly in underserved regions, accelerating diagnosis and timely intervention for neuropathic conditions.

The increasing prevalence of chronic pain and the urgent need for safer treatment alternatives are driving the development of next-generation therapies. Manufacturers are focusing on innovative drug pipelines that include non-opioid medications, gene therapies, monoclonal antibodies, and biosimilars designed to address both acute and chronic forms of neuropathic pain. These breakthrough therapies aim to provide targeted, long-lasting relief while minimizing side effects, representing a major leap forward in pain management.

Based on drug class, anticonvulsants continue to dominate the market and are expected to grow at a CAGR of 8.5%, reaching USD 7.8 billion by 2034. Widely prescribed medications like pregabalin, gabapentin, and carbamazepine are recognized as first-line treatments due to their high efficacy and favorable safety profiles. Their extensive use is especially notable in the treatment of diabetes-induced neuropathy, postherpetic neuralgia, and spinal cord injuries. As chronic disease incidence rises, so does the adoption of these proven medications, reinforcing their stronghold in the market.

When it comes to indications, diabetic neuropathy accounted for USD 3 billion in revenue in 2024. The escalating number of diabetic patients globally is generating sustained demand for long-term treatment solutions. Increased insurance coverage and reimbursement for neuropathic treatments are making therapies such as pregabalin and capsaicin patches more accessible to patients, improving adherence and outcomes.

The U.S. Neuropathic Pain Treatment Market alone was valued at USD 3.3 billion in 2024 and is anticipated to witness significant growth ahead. This rise is primarily due to the country's aging population and the rising prevalence of conditions like cancer, diabetes, and shingles. Federal restrictions on opioid prescriptions are also reinforcing the demand for non-opioid alternatives, encouraging a major shift in treatment dynamics.

Assertio Therapeutics, Glenmark Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline, Biogen, Grunenthal, Mallinckrodt Pharmaceuticals, Novartis, Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Vertex Pharmaceuticals are among the leading companies shaping this dynamic landscape. These firms are actively expanding their therapeutic pipelines and forging strategic alliances with research organizations to bring novel treatments to market faster and more effectively.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neuropathic pain disorders
    • 3.2.1.2 Advancements in drug development and novel therapies
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Increasing awareness towards timely treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of neuropathic pain medications
    • 3.2.2.2 Side effects and risk of drug abuse
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Anticonvulsants
• 5.3 Antidepressants
• 5.4 Opioids
• 5.5 Capsaicinoids
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetic neuropathy
• 6.3 Postherpetic neuralgia
• 6.4 Trigeminal neuralgia
• 6.5 Chemotherapy-induced peripheral neuropathy
• 6.6 HIV-associated neuropathy
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Assertio Therapeutics
• 10.2 Biogen
• 10.3 Cipla
• 10.4 Dr. Reddy’s Laboratories
• 10.5 Eli Lilly and Company
• 10.6 GlaxoSmithKline
• 10.7 Glenmark Pharmaceuticals
• 10.8 Grunenthal
• 10.9 Johnson & Johnson
• 10.10 Mallinckrodt Pharmaceuticals
• 10.11 Novartis
• 10.12 Pfizer
• 10.13 Sun Pharmaceutical Industries
• 10.14 Teva Pharmaceutical Industries
• 10.15 Vertex Pharmaceuticals